Envestnet Asset Management
TRIB

Envestnet Asset Management’s Trinity Biotech TRIB Stock Holding History

Envestnet Asset Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-354
Closed -$56.5K – 4082
2023
Q1 		$56.5K Sell
354
-316
-47% -$48.9K ﹤0.01% 3841
2022
Q4 		$99.5K Hold
670
– – ﹤0.01% 3816
2022
Q3 		$108K Buy
670
+16
+2% +$3.1K ﹤0.01% 3723
2022
Q2 		$120K Hold
654
– – ﹤0.01% 3738
2022
Q1 		$104K Sell
654
-85
-12% -$14.7K ﹤0.01% 3798
2021
Q4 		$159K Buy
+739
New +$210K ﹤0.01% 3697
2015
Q1 		– Sell
-4
Closed -$11K – 2389
2014
Q4 		$11K Sell
4
-6
-60% -$15.5K ﹤0.01% 1941
2014
Q3 		$27K Sell
10
-1
-9% -$3.25K ﹤0.01% 1762
2014
Q2 		$39K Hold
11
– – ﹤0.01% 1534
2014
Q1 		$41K Hold
11
– – ﹤0.01% 1429
2013
Q4 		$41K Buy
11
+2
+22% +$7.2K ﹤0.01% 1281
2013
Q3 		$29K Buy
+9
New +$26.3K ﹤0.01% 1365

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $514M AUM 29.58% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Envestnet Asset Management's TRIB Position: Q2 2023 in Review

Envestnet Asset Management sold out of Trinity Biotech (TRIB) in Q2 2023, closing a stake of 354 shares — an estimated $56.5K sold.

Envestnet Asset Management first reported a position in TRIB in Q3 2013 and held it in 12 quarters. The position peaked at $159K in Q4 2021. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2023.

  • Envestnet Asset Management reported no remaining Trinity Biotech position as of Q2 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 354 Trinity Biotech shares in Q2 2023, an estimated $56.5K.
  • Envestnet Asset Management first reported a position in Trinity Biotech in Q3 2013 and held it in 12 quarters.
  • Envestnet Asset Management's Trinity Biotech position peaked at $159K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2023.

Based on Envestnet Asset Management's 13F filing for Q2 2023, filed 4 Aug 2023.